AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.

about

Benchmarking QSP Models Against Simple Models: A Path to Improved Comprehension and Predictive Performance

P2860

Q58719005-DC3475FA-2125-458D-AE2C-5B2B5E60B5D4

P2860

AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.

Item

http://www.wikidata.org/entity/Q38856152

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

AFIR: A Dimensionless Potency ...... vity of Monoclonal Antibodies.

@en

type

Item

label

AFIR: A Dimensionless Potency ...... vity of Monoclonal Antibodies.

@en

prefLabel

AFIR: A Dimensionless Potency ...... vity of Monoclonal Antibodies.

@en

P1476

AFIR: A Dimensionless Potency ...... vity of Monoclonal Antibodies.

@en

P2093

A M Stein

http://www.w3.org/2001/XMLSchema#string

R Ramakrishna

http://www.w3.org/2001/XMLSchema#string

P2860

A mechanistic tumor penetration model to guide antibody drug conjugate design

Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.

From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.

Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.

On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.

On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

P304

258-266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12169

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28375563

http://www.w3.org/2001/XMLSchema#string

P932

5397564

http://www.w3.org/2001/XMLSchema#string

AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.

about

P2860

P2860

AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932